Identification of HER-2/neu Protein Expression in the Breast Cancer


Authors: A. Skálová;  T. Vaněček 3;  F. Lošan 4;  Papoutsidesová 4;  J. Fínek 5
Authors‘ workplace: Patologicko-anatomický ústav LF UK, Plzeň 2Bioptická laboratoř s. r. o., Plzeň 3Patologicko-anatomický ústav, Laboratoř speciální diagnostiky FN, Plzeň 4Genetická ambulance s laboratoří, Plzeň 5Radioterapeutické a onkologické oddělení FN, Plzeň 1
Published in: Čas. Lék. čes. 2003; : 93-98
Category:

Overview

Background.
HER-2/neu protein overexpression has been shown to be an independently adverse prognostic andpredictive factor in patients with breast cancer. Recently, HER-2/neu overexpression has gained therapeuticimplications: It has been shown that in patients with breast cancer the use of trastuzumab/HerceptinTM, therecombinant humanized monoclonal antibody directed against extracellular domain of HER-2/neu molecule, canblock the HER-2/neu protein activation and bring about a clinical remission. Following these developments, demandfor pathologists to evaluating properly HER-2/neu in breast cancer specimens has been rapidly increasing.Methods and Results. In our series of 449 cases of breast cancer, HER-2/neu protein and gene were examined bymeans of immunohistochemistry and fluorescence in situ hybridization respectively. Results of HER-2/neu studywere compared with the hormonal status, cancer grade and proliferation activity as assessed using immunohistochemistrywith MIB1 antibody. All seven cases of breast cancer with strong overexpression of HER-2/neu (score 3+)manifested a gene amplification. In contrast, among 11 cases of breast cancers with mild HER-2/neu overexpression(score 2+), the gene amplification was demonstrated in 5 cases only (45 %).Conclusions. Immunohistochemical assessment and fluorescence in situ hybridization (FISH) are complementarymethods for detection of HER-2/neu status in breast cancer. While immunohistochemistry is an excellent screeningmethod, FISH should be used for the confirmation of positive results before the Herceptin treatment.

Key words:
breast cancer, HER-2/neu, oncoprotein cerbB2, immunohistochemistry, FISH.

Full text is not available online.
If interested in a scan of this journal, contact NTO ČLS JEP.

Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account